Reliability and Validity of EuroQol-5 Dimensions-5 Levels in Patients with Hematologic Malignancies: A Cross-Sectional Study
Author(s)
Wei Qin, MD, PhD1, Ya Chen, MD1, Yuyuan Ouyang, MD1, Hong Xiao, MD1, Dan Yu, MSc1, Cong Zeng, MD, PhD1, Jinbiao Chen, MD1, Tingyin Chen, MSc1, Huiqing Huang, MD2, Zhaoxin Qian, MD, PhD1, Yajing Xu, MD, PhD1, Wendong Chen, MD, PhD3;
1Xiangya Hospital of Central South University, Changsha, China, 2Changsha Normin Health Technology Ltd, Changsha, China, 3Normin Health Consulting Ltd, Mississauga, ON, Canada
1Xiangya Hospital of Central South University, Changsha, China, 2Changsha Normin Health Technology Ltd, Changsha, China, 3Normin Health Consulting Ltd, Mississauga, ON, Canada
Presentation Documents
OBJECTIVES: Hematologic malignancies cause significant disruptions to health-related quality of life (HRQoL), which has become an important outcome measure for treatment assessment. This study aimed to assess reliability and validity of EuroQol-5 Dimensions-5 Levels (EQ-5D) in Chinese patients with multiple myeloma (MM), acute leukemia (AL), and lymphoma.
METHODS: A cross-sectional study used time-trade off (TTO) and EQ-5D to assess the HRQoL for 158 patients admitted to a Chinese tertiary hospital with MM, AL, or lymphoma. The reliability and validity of EQ-5D in these patients were assessed using Cronbach’s α analysis and Spearman’s rank correlation analysis, which took TTO-elicited utility as reference. The Structural validity of EQ-5D utility was further assessed using factor analysis. Multivariate linear regression analyses were performed to validate the associations between patient characteristics and health utility measured by EQ-5D and TTO.
RESULTS: The self-assessed EQ-5D utility for MM were associated with higher Cronbach’s α (0.899) than that for AL (0.791) and lymphoma (0.730). The correlation between the self-assessed EQ-5D utility and TTO-elicited utility for MM was stronger than that for AL and lymphoma (coefficient: 0.538 vs. 0.230 vs. 0.386). The structural validity of self-assessed EQ-5D utility for MM appeared higher than the other two diseases by having the highest KMO value (0.829) and chi square value of Bartlett’s test (195.494). The multivariate linear regression analyses in the included patients observed more consistent pattern for the associations between patient characteristics and the health utility through self-assessed EQ-5D (coefficient: -0.807 to 0.254) and TTO (coefficient: -0.163 to 0.159). Similar trends were also observed for proxy-assessed EQ-5D utility for the included patients.
CONCLUSIONS: The EQ-5D is a reliable and valid tool for measuring health utility in patients with MM; however, it appears to be less suitable for patients with AL and lymphoma.
METHODS: A cross-sectional study used time-trade off (TTO) and EQ-5D to assess the HRQoL for 158 patients admitted to a Chinese tertiary hospital with MM, AL, or lymphoma. The reliability and validity of EQ-5D in these patients were assessed using Cronbach’s α analysis and Spearman’s rank correlation analysis, which took TTO-elicited utility as reference. The Structural validity of EQ-5D utility was further assessed using factor analysis. Multivariate linear regression analyses were performed to validate the associations between patient characteristics and health utility measured by EQ-5D and TTO.
RESULTS: The self-assessed EQ-5D utility for MM were associated with higher Cronbach’s α (0.899) than that for AL (0.791) and lymphoma (0.730). The correlation between the self-assessed EQ-5D utility and TTO-elicited utility for MM was stronger than that for AL and lymphoma (coefficient: 0.538 vs. 0.230 vs. 0.386). The structural validity of self-assessed EQ-5D utility for MM appeared higher than the other two diseases by having the highest KMO value (0.829) and chi square value of Bartlett’s test (195.494). The multivariate linear regression analyses in the included patients observed more consistent pattern for the associations between patient characteristics and the health utility through self-assessed EQ-5D (coefficient: -0.807 to 0.254) and TTO (coefficient: -0.163 to 0.159). Similar trends were also observed for proxy-assessed EQ-5D utility for the included patients.
CONCLUSIONS: The EQ-5D is a reliable and valid tool for measuring health utility in patients with MM; however, it appears to be less suitable for patients with AL and lymphoma.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PT33
Topic
Patient-Centered Research
Topic Subcategory
Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology